

# Table of contents

Introduction	5
1. Alzheimer's Disease	5
2. Protein misfolding	7
3. The Amyloid- $\beta$ peptide	10
4. The amyloid hypothesis and pathogenic pathways	14
5. Biomarkers	19
6. Blood-based biomarkers in AD	24
7. Core immunochemistry approaches for AD research and clinical practice	26
8. Sequence-specific and conformational antibodies against A $\beta$	27
9. Anti-A $\beta$ monoclonal antibodies approved in clinical trials for AD treatment	29
10. Camelid antibodies	31
11. Aim of the thesis	33
12. Introduction: figures and tables	34
 Chapter 1	
Materials and Methods	47
1. First section	47
2. Second section	51
3. Third section	57

## Chapter 2

<i>First Section: Putative CSF biomarkers of Alzheimer's disease based on the novel concept of generic protein misfolding and proteotoxicity: the PRAMA cohort</i>	65
1. Demographic characteristics and classical CSF biomarker distributions of the PRAMA cohort	65
2. Non-AD and AD CSFs have similar circular dichroism spectra and parameters	66
3. Non-AD and AD CSFs have different wavelengths of maximum fluorescence emission	67
4. Non-AD and AD CSFs have different quantities of protein aggregates	67
5. Non-AD and AD CSFs have different abilities to destabilize cell membranes.	68
6. Evidence for fluorescence, DLS, and toxicity parameters as potential AD biomarkers	69
7. Comparison between novel and classical biomarkers.	70
8. Chapter 2: figures and tables	72

## Chapter 3

<i>Second Section: A single domain antibody detects and neutralises toxic A<math>\beta</math><sub>42</sub> oligomers in the Alzheimer's disease CSF</i>	79
1. DesAb-O selectively detects synthetic A $\beta$ <sub>42</sub> oligomers <i>in vitro</i>	79
2. DesAb-O detects synthetic A $\beta$ <sub>42</sub> oligomers bound to neuronal membrane and internalized into the cytosol	80
3. DesAb-O inhibits the interaction of A $\beta$ <sub>42</sub> oligomers with neuronal membranes preventing mitochondrial dysfunction	81
4. DesAb-O detects A $\beta$ <sub>42</sub> oligomers in the CSF of AD patients <i>in vitro</i>	82
5. DesAb-O detects A $\beta$ <sub>42</sub> oligomers present in AD CSFs upon their interaction with neuronal cells	84
6. DesAb-O prevents neuronal dysfunction induced by the CSFs of AD patients.	85
7 Chapter 3: figures and tables	86

## Chapter 4

<i>Third Section: Design of a dimeric-nanobody specific for A<math>\beta</math><sub>42</sub> oligomers: the Dimeric-DesAb-O</i>	95
---	----

1. Dimeric-DesAb-O design	95
2. Structural characterization of the Dimeric-DesAb-O	96
3. The Dimeric-DesAb-O slows down A $\beta$ <sub>42</sub> aggregation in a dose-dependent manner	96
4. Dimeric-DesAb-O has improved specificity of binding for A $\beta$ <sub>42</sub> oligomers	97
5. Dimeric-DesAb-O induces morphological and structural changes in A $\beta$ <sub>42</sub> fibrils	98
6. Characterisation of A $\beta$ <sub>42</sub> aggregates with ThT assay, dot blot assay and STED microscopy	100
7. A $\beta$ <sub>42</sub> oligomeric species obtained after 8 hours of incubation exhibit high toxicity	101
8. The Dimeric-DesAb-O detects A $\beta$ <sub>42</sub> oligomers interacting with cellular membranes and internalized into the cytoplasm	101
9. The Dimeric-DesAb-O inhibits the interaction of A $\beta$ <sub>42</sub> oligomers with neuronal membranes preventing A $\beta$ <sub>42</sub> -induced neurotoxicity	102
10. The Dimeric-DesAb-O prevent from the dysregulation of cytosolic Ca <sup>2+</sup> homeostasis and the mitochondrial dysfunction induced by A $\beta$ <sub>42</sub> oligomers	103
11. The Dimeric-DesAb-O prevents toxic effects induced by the CSFs of AD patients	104
12. Chapter 4: figures and tables	105
 Chapter 5	
Discussion	117
 Chapter 6	
Conclusions and future perspectives	127
 References	129
 Index of names	173